Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244431 | 0.83 | HSP90AB1 (0.67) | HSP90AB1HSP90AA1NUDT1TNKSMAP4K4 | |
| SCHEMBL2158386 | 0.81 | HSP90AB1 (0.71) | HSP90AB1NUDT1TNKSACHEGSK3B | |
| SCHEMBL2158416 | 0.80 | HSP90AB1 (0.56) | HSP90AB1ACHEGSK3BHCRTR2MET | |
| SCHEMBL13575004 | 0.76 | HSP90AA1 (0.34) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL13575000 | 0.76 | HSP90AB1 (0.45) | HSP90AB1NUDT1TNKS | |
| SCHEMBL2158462 | 0.75 | MAP4K4 (0.42) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL14406022 | 0.75 | HSP90AB1 (0.58) | HSP90AB1 | |
| SCHEMBL2158650 | 0.74 | HSP90AB1 (0.57) | HSP90AB1 | |
| SCHEMBL2079662 | 0.74 | HSP90AB1 (0.66) | HSP90AB1HSP90AA1NUDT1MAP4K4CSNK1G2 | |
| SCHEMBL2605039 | 0.74 | HSP90AB1 (0.63) | HSP90AB1NUDT1TNKSGSK3BPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | claimed |
| EP-2313412-B1 | NOVEL DERIVATIVES OF PYRROLOINDOLE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-8178687-B2 | Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof | SANOFI-AVENTIS (FR) | 2012-05-15 | — | — | US | disclosed |
| US-8178687-B2 | Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof | SANOFI-AVENTIS (FR) | 2012-05-15 | — | — | US | disclosed |
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| WO-2009153516-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885NUDT1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.